Roche's Subcutaneous OCREVUS One-year Data Demonstrates Near-complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS
Roche's Subcutaneous OCREVUS One-year Data Demonstrates Near-complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS
Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated near-complete suppression of relapse activity (97%) and MRI lesions (97.2%) through 48 weeks
The twice-yearly, 10-minute SC injection has the potential to expand the usage of OCREVUS to treatment centres without IV infrastructure or with IV capacity limitations
U.S. FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024
Basel, 17 April 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today data from the Phase III OCARINA II study (S31.006) of OCREVUS (ocrelizumab), an investigational twice-yearly, 10-minute subcutaneous (SC) injection. Results showed near-complete suppression of clinical relapses and brain lesions in people with relapsing or primary progressive multiple sclerosis (RMS or PPMS) which reinforce the potential benefits of this investigational formulation. Treatment with OCREVUS SC led to rapid and sustained B-cell depletion in the blood. The data will be presented as an oral presentation at the 76th American Academy of Neurology (AAN) Annual Meeting taking place April 13-18 in Denver and has been recognised as an abstract of distinction by the AAN scientific committee.
"With a full year of data demonstrating near-complete suppression of relapse activity and minimal progression of lesion development, this 10-minute subcutaneous OCREVUS injection shows results that are consistent with the long-established benefits of intravenous OCREVUS," said Levi Garraway, M.D., Ph.D., Roche's chief medical officer and head of Global Product Development. "We look forward to continuing ongoing conversations with regulatory bodies worldwide to potentially bring an additional treatment option to more people living with MS, in a shorter injection time."
Updated, longer-term results showed that OCREVUS SC injection (920 mg; n=236; both treatment arms [OCR SC/SC and OCR IV/SC]) resulted in near-complete suppression of relapse activity (97.2% had no relapse during the treatment phase) and MRI up to 48 weeks with an ARR of 0.04, and most patients having no T1 gadolinium-enhancing (T1 Gd+) lesions and no new/enlarging T2 lesions. These lesion types are markers of active inflammation and burden of disease, respectively. Additionally, in exploratory patient reported outcome measures (n=52) patients reported a high level of satisfaction (92.3% were satisfied or very satisfied) and convenience (90.1% felt it was convenient or very convenient) with OCREVUS SC injection.
"Updated results from OCARINA II further underline the potential benefits of subcutaneous OCREVUS for patients with both relapsing and progressive forms of MS," said Scott Newsome, D.O., lead author, Johns Hopkins University School of Medicine. "Patients treated with subcutaneous OCREVUS experienced appropriate B-cell suppression and impressive near-complete suppression of new inflammatory disease activity. These results demonstrate the potential of subcutaneous OCREVUS as a treatment option that can be matched to the individual needs of people with MS and healthcare professionals."
Additional data continued to show that the safety profile of OCREVUS SC injection was consistent with the well-established safety profile of OCREVUS IV infusion. No new safety signals were identified for OCREVUS SC. The most common adverse events in the OCREVUS SC group were injection reactions (51.5% of all exposed patients), including erythema (34.8%; skin redness or irritation), pain (17.2%), swelling (9.4%) and pruritus (5.6%; skin itching), all of which were either mild or moderate and none of which led to treatment withdrawal. A total of seven serious AEs were experienced by three (2.6%) and four (3.4%) patients in the OCREVUS SC injection and IV infusion groups, respectively.
The OCARINA II abstract was selected as an abstract of distinction by the AAN, based on the quality of the study and the interest to the neurology community.
The twice-yearly, 10-minute SC injection has the potential to expand the usage of OCREVUS to treatment centres without IV infrastructure or with IV capacity limitations. Data from the Phase III OCARINA II trial were submitted to health authorities around the world following the first presentation of these results during ECTRIMS-ACTRIMS 2023. Both the European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA) have accepted Roche's submissions, with a target decision date of mid-2024 for the EMA and September 2024 for the FDA.
More than 300,000 people with MS have been treated with OCREVUS IV globally. OCREVUS IV is approved in more than 100 countries across North America, South America, the Middle East, Eastern Europe, Asia, Australia, Switzerland, the United Kingdom and the EU.
Roche is committed to advancing innovative clinical research programmes to broaden the scientific understanding of MS, further reducing disability progression in RMS and PPMS and improving the treatment experiences for those living with the disease. There are more than 30 ongoing OCREVUS clinical trials designed to help us better understand MS and its progression.
About the subcutaneous formulation of OCREVUS (ocrelizumab)
The investigational subcutaneous (SC) formulation combines OCREVUS with Halozyme Therapeutics' Enhanze drug delivery technology.
OCREVUS is a humanised monoclonal antibody designed to target CD20-positive B cells, a specific type of immune cell thought to be a key contributor to myelin (nerve cell insulation and support) and axonal (nerve cell) damage. This nerve cell damage can lead to disability in people with MS. Based on preclinical studies, OCREVUS binds to CD20 cell surface proteins expressed on certain B cells, but not on stem cells or plasma cells, suggesting that important functions of the immune system may be preserved.
The Enhanze drug delivery technology is based on a proprietary recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that locally and temporarily degrades hyaluronan – a glycosaminoglycan or chain of natural sugars in the body – in the SC space. This increases the permeability of the tissue under the skin, allowing space for large molecules like OCREVUS to enter, and enables the SC formulation to be rapidly dispersed and absorbed into the bloodstream.
OCREVUS IV is the first and only therapy approved for both RMS (including relapsing-remitting MS [RRMS] and active, or relapsing secondary progressive MS [SPMS], in addition to clinically isolated syndrome [CIS] in the U.S.) and PPMS. OCREVUS IV is administered by intravenous infusion every six months. The initial dose is given as two 300 mg infusions given two weeks apart. Subsequent doses are given as single 600 mg infusions.
III 期研究的結果顯示,皮下(SC)注射與靜脈輸注一致,並且在 48 周內幾乎完全抑制了復發活動(97%)和 MRI 病變(97.2%)
每年兩次、每次10分鐘的SC注射有可能將OCREVUS的使用範圍擴大到沒有靜脈輸液基礎設施或靜脈輸液能力限制的治療中心
美國食品和藥物管理局根據OCARINA II的數據接受了申請,預計歐盟將在2024年中期獲得批准,美國預計在2024年9月獲得批准
巴塞爾,2024年4月17日——羅氏(SIX:RO,ROG;OTCQX:RHHBY)今天公佈了OCREVUS(奧克雷珠單抗)的三期OCARINA II研究(S31.006)的數據,這是一項研究性的,每年兩次,每次10分鐘的皮下(SC)注射。結果顯示,復發或原發性進行性多發性硬化症(RMS或PPMS)患者的臨床復發和腦部病變幾乎完全得到抑制,這增強了這種研究性製劑的潛在益處。使用OCREVUS SC進行治療會導致血液中的B細胞快速持續消耗。這些數據將在4月13日至18日在丹佛舉行的第76屆美國神經病學會(AAN)年會上以口頭陳述的形式公佈,並已被AAN科學委員會認可爲傑出摘要。
羅氏首席醫學官兼全球產品開發主管李維·加拉威醫學博士說:“整整一年的數據表明,復發活動幾乎完全抑制,病變發展進展微乎其微,這種10分鐘的皮下OCREVUS注射的效果與靜脈注射OCREVUS的長期益處一致。”“我們期待與全球監管機構繼續進行對話,以便有可能在更短的注射時間內爲更多的多發性硬化症患者提供額外的治療選擇。”
更新的長期結果顯示,OCREVUS SC 注射(920 mg;n=236;兩個治療組 [OCR SC/SC 和 OCR IV/SC])幾乎完全抑制了復發活動(97.2% 在治療階段沒有復發)和長達 48 周的 MRI,ARR 爲 0.04,大多數患者沒有 T1 鎵增強型 (T1 Gd+) 病變,也沒有新的/擴大的 T2 病變。這些病變類型分別是活動性炎症和疾病負擔的標誌。此外,在探索性患者報告的預後衡量標準(n=52)中,患者表示OCREVUS SC注射的滿意度很高(92.3%表示滿意或非常滿意)和便利性(90.1%的人認爲很方便或非常方便)。
約翰·霍普金斯大學醫學院主要作者、博士斯科特·紐瑟姆說:“OCARINA II的最新結果進一步突顯了皮下OCREVUS對復發和進行性多發性硬化症患者的潛在益處。”“接受皮下OCREVUS治療的患者經歷了適當的B細胞抑制,並對新的炎症性疾病活性進行了令人印象深刻的近乎完全的抑制。這些結果表明,皮下OCREVUS有可能作爲一種治療選擇,可以滿足多發性硬化症患者和醫療保健專業人員的個人需求。”
其他數據繼續顯示,OCREVUS SC注射劑的安全性與OCREVUS IV輸液的既定安全性一致。OCREVUS SC 沒有發現新的安全信號。OCREVUS SC組中最常見的不良事件是注射反應(佔所有暴露患者的51.5%),包括紅斑(34.8%;皮膚髮紅或刺激)、疼痛(17.2%)、腫脹(9.4%)和瘙癢(5.6%;皮膚瘙癢),均爲輕度或中度,均未導致停止治療。在OCREVUS SC注射組和靜脈輸液組中,三名(2.6%)和四名(3.4%)患者共經歷了七例嚴重不良事件。
根據研究質量和神經病學界的興趣,OCARINA II摘要被AAN選爲區分摘要。
每年兩次、每次10分鐘的SC注射有可能將OCREVUS的使用範圍擴大到沒有靜脈輸液基礎設施或靜脈輸液能力限制的治療中心。在ECTRIMS-ACTRIMS 2023年期間首次公佈這些結果後,OCARINA III期三期試驗的數據已提交給世界各地的衛生當局。歐洲藥品管理局(EMA)和美國食品藥品監督管理局(FDA)都接受了羅氏的申請,EMA的目標決定日期爲2024年年中,FDA的目標決定日期爲2024年9月。
全球已有超過30萬多發性硬化症患者接受了OCREVUS IV治療。OCREVUS IV 已在北美、南美、中東、東歐、亞洲、澳大利亞、瑞士、英國和歐盟的 100 多個國家獲得批准。
羅氏致力於推進創新的臨床研究計劃,以擴大對多發性硬化症的科學理解,進一步減少多發性硬化症和PPMS的殘疾進展,改善該病患者的治療體驗。目前有30多項OCREVUS臨床試驗正在進行中,旨在幫助我們更好地了解多發性硬化症及其進展。
關於 OCREVUS(奧克雷珠單抗)的皮下製劑
研究中的皮下(SC)配方將OCREVUS與Halozyme Therapeutics的Enhanze藥物遞送技術相結合。
OCREVUS 是一種人源化單克隆抗體,旨在靶向 CD20 陽性 B 細胞,這是一種特殊類型的免疫細胞,被認爲是造成髓磷脂(神經細胞隔熱和支持)和軸突的(神經細胞)損傷的關鍵因素。這種神經細胞損傷可能導致多發性硬化症患者殘疾。根據臨床前研究,OCREVUS 與某些 B 細胞上表達的 CD20 細胞表面蛋白結合,但不會與幹細胞或漿細胞上表達的CD20細胞表面蛋白結合,這表明免疫系統的重要功能可以保留。
Enhanze藥物遞送技術基於專有的重組人透明質酸酶PH20(rhUpH20),該酶可在SC空間中局部暫時降解透明質酸(一種糖胺聚糖或體內天然糖鏈)。這增加了皮膚下組織的滲透性,爲 OCREVUS 等大分子留出了進入的空間,並使 SC 配方能夠迅速分散並吸收到血液中。
OCREVUS IV是第一種也是唯一一種獲准同時用於RMS(包括復發緩解型多發性硬化症 [RRMS] 和活動性或複發性繼發性進行性多發性硬化症 [SPMS],以及美國臨床孤立綜合徵 [CIS])和PPMS的療法。OCREVUS IV 每六個月通過靜脈輸液給藥一次。初始劑量爲兩次 300 mg 的輸液,間隔兩週。後續劑量以單次 600 mg 輸液的形式給出。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧